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Abstract
Objective. To review the literature on progress regarding (1)
effectiveness of vaccines for prevention of otitis media (OM)
and (2) development of vaccine antigens for OM bacterial
and viral pathogens.
Data Sources. PubMed database of the National Library of
Science.
Review Methods. We performed literature searches in
PubMed for OM pathogens and candidate vaccine antigens,
and we restricted the searches to articles in English that
were published between July 2011 and June 2015. Panel
members reviewed literature in their area of expertise.
Conclusions. Pneumococcal conjugate vaccines (PCVs) are
somewhat effective for the prevention of pneumococcal
OM, recurrent OM, OM visits, and tympanostomy tube
insertions. Widespread use of PCVs has been associated
with shifts in pneumococcal serotypes and bacterial patho-
gens associated with OM, diminishing PCV effectiveness
against AOM. The 10-valent pneumococcal vaccine contain-
ing Haemophilus influenzae protein D (PHiD-CV) is effective
for pneumococcal OM, but results from studies describing
the potential impact on OM due to H influenzae have been
inconsistent. Progress in vaccine development for H influen-
zae, Moraxella catarrhalis, and OM-associated respiratory
viruses has been limited. Additional research is needed to
extend vaccine protection to additional pneumococcal sero-
types and other otopathogens. There are likely to be licen-
sure challenges for protein-based vaccines, and data on
correlates of protection for OM vaccine antigens are
urgently needed.
Implications for Practice. OM continues to be a significant
health care burden globally. Prevention is preferable to
treatment, and vaccine development remains an important
goal. As a polymicrobial disease, OM poses significant but
not insurmountable challenges for vaccine development.
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A
cute otitis media (AOM) is one of the most com-
monly diagnosed childhood infections and a leading
diagnosis for the prescription of antibiotics.1 The 3
primary bacterial pathogens that cause AOM are Streptococcus
pneumoniae, nontypeable Haemophilus influenzae (NTHi), and
Moraxella catarrhalis. Virtually all cases of AOM occur fol-
lowing or concurrent with a symptomatic viral respiratory tract
infection.2 The etiology of otitis media (OM) is continually
undergoing changes associated with widespread use of pneu-
mococcal conjugate vaccines (PCVs), which alter nasopharyn-
geal colonization patterns, particularly the distribution of
pneumococcal serotypes. In clinical practice, AOM is managed
empirically. Controversies exist regarding the use of antibiotics
for treatment of OM, and antibiotic resistance is a major
public health concern. Thus, new methods to prevent OM and
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its associated sequelae are urgently needed. Vaccines represent
a promising approach to reduce the burden of OM globally.
However, OM is a polymicrobial disease and poses significant
challenges for vaccine development. The goal of this report is
to provide an update on the role of conjugate and influenza
virus vaccines in preventing OM and progress toward identifi-
cation of new vaccine targets over the past 4 years.
Methods
The PubMed database of the National Library of Medicine
was used to search for articles related to vaccines and vaccine
antigens for OM. The PubMed literature search was restricted
to articles published between July 2011 and June 2015.
Keywords included Streptococcus pneumoniae, Haemophilus
influenzae, or Moraxella catarrhalis and vaccine, vaccine
antigens, and OM. Searches were also conducted on each
otopathogen and vaccine antigen discussed in the 2011 report
of the 10th Research Conference on Recent Advances in
Otitis Media.3 Original research, reviews, and editorials were
included, and searches were limited to articles published in
English. Panel members reviewed literature in their area of
expertise, and articles were included if they were judged to
be scientifically sound; explicit inclusion, exclusion, and
quality criteria were not used to select articles. Panel mem-
bers met and discussed recent advances in the field and an
early draft of the report at the Postsymposium Research
Conference to the 18th International Symposium on Recent
Advances in Otitis Media. The final draft was reviewed and
approved by all panel members.
Discussion
Etiology of OM
Culture of middle ear fluid has been the gold standard for
determining AOM etiology. Table 1 shows results of cul-
tures of middle ear fluid obtained by tympanocentesis or
spontaneous perforation of the tympanic membrane.
Biofilms are communities of bacteria encased in a matrix
present in the middle ear.4 Effusions recovered from the
middle ear are often sterile by culture but contain abundant
viable pathogens within biofilms, which can be detected by
polymerase chain reaction.5,6 Studies that use polymerase
chain reaction to detect pathogens in middle ear fluids
detect pathogens at higher proportions when compared with
studies that use culture alone, particularly in the case of
NTHi and M catarrhalis (Table 1).7 Recognition of the role
of biofilms in OM has important implications for under-
standing the etiology of OM and in designing more effective
therapies as well as rational vaccine development strategies.
Relying solely on culture as the end point in clinical trials
of OM will assess only a subset of cases, and studies to
assess vaccine efficacy and effectiveness should take into
account the role of biofilms and culture-negative OM.
Effectiveness of Conjugate Vaccines for OM
Since 2000, many countries have implemented vaccine pro-
grams using the 7-valent PCV (PCV7; Prevnar). Earlier
studies of PCV7 demonstrated a reduction in OM and naso-
pharyngeal colonization by the 7 pneumococcal vaccine ser-
otypes, replacement by nonvaccine serotypes, and increases
in the proportion of OM cases due to NTHi and M catarrha-
lis.3,8-12 Since 2011, data are available that depict trends
from regions where the vaccine has recently been intro-
duced. Increasing use of the 13-valent PCV (PCV13) and
the 10-valent pneumococcal vaccine with H influenzae pro-
tein D (Synflorix; PHiD-CV) as the carrier molecule has
resulted in additional changes in nasopharyngeal coloniza-
tion patterns and the distribution of pathogens causing
OM.13
PCV7 and PCV13. An evaluation of 5 PCV vaccine trials
with OM end points showed a combined vaccine efficacy
against vaccine serotypes of 60%, an overall decrease of
pneumococcal AOM of 25% to 52%, and an overall reduc-
tion in all cause AOM cases of 20.4% to 7%.14
Observational studies demonstrate effectiveness of PCV
Table 1. Etiology of Otitis Media Based on Culture and PCR of Middle Ear Fluids from Studies Published from July 2011 to June 2015.
Middle Ear Fluid Culture (MEF Positive, %) Middle Ear Fluid PCR (MEF Positive, %)
Study Site Diagnosisa MEF, n S pneumo NTHi Mcat S pneumo NTHi Mcat
US104 OME 169 ND ND ND 12 47 34
US104 AOM 38 ND ND ND 6 76 30
Spain12 Complicated OM 105 20 42 2 39 61 ND
Russia105 AOM 541 20 3 2 ND ND ND
US106 AOM 530 29 37 20 ND ND ND
New Zealand7 Complicated OM 325 8 19 8 23 43 56
Israel16 Complicated OM 295 20 12 1 ND ND ND
Costa Rica17 AOM and recurrent AOM 456 19 25 5 ND ND ND
Abbreviations: AOM, acute otitis media; Mcat, Moraxella catarrhalis; MEF, middle ear fluid; ND, no data; NTHi, nontypeable Haemophilus influenzae; OM, otitis
media; OME, otitis media with effusion; PCR, polymerase chain reaction; S pneumo, Streptococcus pneumoniae.
aComplicated OM includes recurrent OM, treatment failure, chronic OM, and OME.
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vaccines. A study in Israel examined AOM incidence from
July 2004 to June 2013 and documented changes following
the stepwise introduction of PCV7 (July 2009) and PCV13
(November 2010).15 Incidence of AOM episodes caused by
S pneumoniae decreased 77%, and there was a nonsignifi-
cant increase in AOM caused by nonvaccine serotypes
when the PCV13 period was compared with the pre-PCV7
period.15 A retrospective study of AOM in Israel showed
that S pneumoniae was present in a significantly higher pro-
portion of middle ear fluids when unvaccinated children
were compared with PCV7- or PCV13-vaccinated children
(69% vs 59% and 50%, respectively).16 A Costa Rican
study showed a lower frequency of S pneumoniae AOM
(17.1% vs 25.5%) and a higher frequency of AOM due to
NTHi (27.4% vs 20.8%) in PCV-vaccinated versus unvacci-
nated children.17
Marom et al analyzed an insurance claims database of a
large managed health care plan in the United States from
2001 to 2011.18 There was a trend toward reduction in
AOM rates per child-year from 2001 to 2011 in children\2
years of age. These trends accelerated in 2010 in association
with the introduction of PCV13. A 19% decline in tympa-
nostomy tube insertion was also observed in 2010 to 2011.
However, tympanic membrane perforations increased from
2001 to 2011.18 Health registry data on children enrolled in
FinOM study demonstrated a 34% (95% confidence inter-
val, 1%-52%) reduction in tympanostomy tube placement in
the PCV-vaccinated group for children aged 2 to 5 years but
no reduction in children aged 6 to 13 years.19 These data
suggest that prevention of AOM, specifically early episodes,
leads to reductions in complex and persistent OM as mea-
sured by tympanostomy tube insertion. Acute mastoiditis—a
complication of OM that initially decreased after introduc-
tion of PCV7—increased with the emergence of pneumo-
coccal serotype 19A.20-22 Kaplan et al recently reported
data suggesting that mastoiditis due to serotype 19A has
begun to decline in the PCV13 era.23 PCV13 was intro-
duced relatively recently, and our understanding of the
global impact of PCV13 on OM and complications of dis-
ease is still incomplete.
Pneumococcal isolates were collected from children
undergoing myringotomy or tympanostomy tube insertion at
8 US children’s hospitals; these data indicated a decline in
PCV13 serotypes (mostly 19A) and that non-PCV13 sero-
types represented ~60% of isolates collected between 2011
and 2013.23 In Australia, serotype 19A was the most
common serotype isolated from middle ear fluids after intro-
duction of PCV7.24 PCVs have also been associated with
changes in the prevalence of antimicrobial resistance. In
most studies, an overall increase in antibiotic resistance has
been seen in association with PCV7 immunization that, to a
large extent, is due to the increased prevalence of strains of
serotype 19A.24-27
PCV7 and PCV13 mount effective and functional
responses in infants and children.28 Although some studies
suggest that otitis-prone infants/children may mount a less
effective response to the vaccine than non-otitis-prone
children,16 other studies have shown equally robust antibody
responses to PCVs in both groups.29-32
PHiD-CV. A phase 3 double-blind study of 20,000 South
American infants showed per-protocol efficacy of PHiD-CV
against pneumococcal AOM and vaccine serotype pneumo-
coccal AOM of approximately 56% and 67%, respectively,
with an overall decrease of 16% in AOM incidence from
any cause.33,34 Leach et al studied indigenous Australian
children vaccinated with PCV7 (2008 and 2009 birth
cohorts) or PHiD-CV (2010 and 2010 birth cohorts) and fol-
lowed them for subsequent OM.35 More than 90% of the
children had some form of OM. The authors observed a sig-
nificant reduction in suppurative OM in PHiD-CV- versus
PCV7-vaccinated children (51% vs 39%, P = .0004). Subtle
differences between the PCV7 and PHiD-CV cohorts and
the use of historical controls limit the evaluation of vaccine
efficacy; however, the study demonstrates that indigenous
Australian children suffer a disproportionate amount of ear
disease despite current strategies for prevention of OM. The
POET study examined an 11-valent PCV with a protein D
carrier and demonstrated efficacy against OM due to S
pneumoniae and NTHi.36 While recent work indicates that
the protein D component of PHiD-CV induces a strong anti-
body response, other studies have raised questions about the
ultimate ability of a protein D–based vaccine to protect
against NTHi disease, as described below.
The protein D component of the vaccine was demonstrated
to be very immunogenic in Chilean,37 Japanese,38 and Mexican
infants39 when administered as part of a normal childhood vac-
cination series. Studies in Korean and Taiwanese infants exam-
ined the immunogenicity of PHiD-CV when coadministered
with H influenzae type b vaccine and reported excellent immu-
nogenicity of protein D.40,41 Moreover, protein D has excellent
immunogenicity in both premature and term infants when admi-
nistered on a normal infant schedule.42 A more recent report
described the relative immunogenicity of PHiD-CV in Dutch
children when coadministered with either DTPa-IPV-Hib
(Pediacel) or DTPa-HBV-IPV/Hib (Infanrix) and found excel-
lent immunogenicity of the protein D component of the vaccine
in both groups.43 Studies examined the ability of immunization
with PHiD-CV to induce an anamnestic antibody response fol-
lowing boosting,44 the immunogenicity of booster and catch-up
doses of the vaccine,45 and the effect of variation in age on the
immunogenicity of individual booster doses.46 In each instance,
the protein D component of the vaccine demonstrated excellent
immunogenicity.
A study of Dutch children compared the ability of immu-
nization with PHiD-CV and PCV7 to prevent colonization
with NTHi. PHiD-CV immunization had no demonstrable
effect on the colonization, acquisition, or bacterial density
of NTHi compared with PCV7.47 Of concern, 3 of the 16
NTHi strains recovered from children in Australia strains
completely lacked the gene that encodes protein D. No sta-
tistically significant reduction in AOM due to NTHi was
observed in the Clinical Otitis Media and Pneumonia
Study.34 Collectively, these studies indicate that a protein
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D–based vaccine might be less broadly protective for OM
due to NTHi than originally envisioned.
Effectiveness of Viral Vaccines for OM
Respiratory viral infection is one of the most important pre-
cipitating factors leading to AOM.1,2 Therefore, vaccines
that prevent respiratory viral infections would likely prevent
AOM. However, influenza is the only OM-associated
respiratory virus for which there is a licensed vaccine.
Influenza vaccines may fail to prevent influenza infection
due to mismatches with circulating influenza strains; it has
been suggested that while nonneutralizing influenza vac-
cines may fail to prevent influenza infection, they could
protect from secondary bacterial infections such as OM.48
Heikkinen et al used pooled data from randomized con-
trolled trials of influenza virus vaccines and reported that
during influenza seasons, the efficacy of the live attenuated
influenza vaccine (LAIV) against all-cause AOM was 7.5%
when compared with placebo.49 They concluded that the
combination of LAIVs and PCVs could further reduce the
incidence of AOM in children. However, in a small study in
92 children, pandemic influenza A/H1N1 vaccine did not
reduce the rate of AOM as compared with that of unvacci-
nated children.50 In 2015, the Cochrane Collaboration con-
cluded that overall influenza vaccination results in a small
reduction in AOM and that the benefits may not justify the
use of influenza vaccine as a strategy to prevent AOM due
to vaccine safety concerns.51
Mina et al reported that mice inoculated with LAIV, which
causes mild infection of the nasopharynx, had decreased pneu-
mococcal and staphylococcal clearance from the nasopharynx
and increased bacterial colonization rates.52 LAIV increased
transmigration to and persistence of pneumococci within the
middle ear.53 The authors suggest that live attenuated vaccine
may increase risk of AOM. More data are needed to determine
whether these data can be extrapolated to humans.
Seppa¨la¨ et al reported reduction in AOM rates in children
after oral live attenuated poliovirus vaccination, which
could be due to the prevention of viral infections caused by
nonpolio viruses.54 However, large-scale impact of the oral
polio vaccine on burden of AOM in children is unknown.
Progress in Identification of New Vaccine
Candidates
S pneumoniae
Due to limitations of PCVs,55 there has been considerable
interest in the development of pneumococcal vaccines that
target common and conserved surface proteins that could
supplement or eventually replace PCVs. In theory, protein-
based vaccines would be simpler and cheaper to produce
than conjugate vaccines. Candidate pneumococcal antigens
and vaccines are summarized in Table 2.
Several pneumococcal protein antigens have been studied
in animal models. Immunization with pneumococcal surface
adhesion A (PsaA) protected against OM in a murine
model.56 A fusion of PsaA and nontoxic pneumolysin (Ply)
produced a more robust Th1/Th17 mucosal response than
each protein alone or immunization with a mix of the 2 pro-
teins.57 A fusion protein consisting of the choline binding
protein A peptide and L460D, a nontoxic pneumolysoid,
was shown to be more broadly protective against pneumo-
coccal disease than pneumolysoid alone in mice, with a
reduction in OM from 55% to 25%.58 Two conserved pro-
teins of unknown function, SP1298 and SP2205, were not
directly tested for prevention of AOM but were used to
immunize mice, and they showed a reduced pneumococcal
load in the nasopharynx, lungs, and blood.59 Immunization
of chinchillas with the chimeric protein RrgB321, a compo-
nent of pneumococcal pilus 1, did not protect against
experimental OM, although a delay in development of dis-
ease was seen.60
Some laboratories have attempted to develop whole-cell
pneumococcal vaccines. A live whole-cell vaccine lacking
FtzY (to stop multiplication of the bacteria) produced
serotype-independent protection against OM that was
CD41 T cell dependent.61 A whole-cell vaccine composed
of an ethanol-killed capsule-deficient S pneumoniae mutant
provided protection against colonization with serotype 4 and
19F strains.62
An inactivated whole-cell vaccine that has undergone a
phase 1 clinical study in healthy US adults demonstrated an
acceptable safety and reactogenicity profile along with
encouraging immune responses.63 This vaccine is appealing
in that it incorporates numerous pneumococcal antigens
and, in preclinical models, demonstrates 2 mechanisms of
protection: protection against nasopharyngeal carriage via a
T cell–mediated mechanism and protection against pneumo-
coccal disease via humoral antibody responses.64 GSK
Biologicals is developing a novel pneumococcal vaccine
that involves the addition of 2 pneumococcal proteins to its
PCV10 Synflorix: pneumococcal histidine triad protein D
(PhtD) and pneumolysin.65 This vaccine candidate has
undergone a number of clinical trials and is currently being
evaluated in infants in the Gambia for an impact on carriage
of nonvaccine serotypes.66 GSK is also evaluating these 2
proteins for their ability to vaccinate children against
AOM.67 Sanofi Pasteur is developing a novel pneumococcal
vaccine that includes 3 proteins: PhtD, pneumolysoid, and
pneumococcal choline binding protein A. This candidate
has also been assessed in a number of trials, including in a
small study in Bangladeshi infants where the vaccine was
found to be immunogenic but did not appear to affect naso-
pharyngeal carriage.68 Finally, Genocea has used its antigen
discovery platform to identify T-cell antigens associated
with protection against pneumococcal nasopharyngeal car-
riage and has initiated clinical studies to assess a trivalent
protein vaccine candidate.69
Ren et al and Xu et al investigated natural antibodies to
pneumococcal proteins in children.70,71 They observed that
the titers against PhtD, pneumococcal choline binding pro-
tein A, and Ply were significantly lower in serum and
middle ear fluid in OM prone as compared with non-OM-
prone children.56,70 Verhaegh et al screened antibodies
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against 18 pneumococcal proteins, including PhtD and Ply,
and showed that there were no differences in IgG, IgA, and
IgM levels when comparing children with recurrent AOM
and chronic OM with effusion.72 Another study demon-
strated that otitis-prone children have a lower percentage of
memory B cells and immunoglobulin production to pneu-
mococcal protein antigens, such as pneumolysin and PhtD/
PhtE, when compared with non-otitis-prone children.73
Nontypeable H influenzae
PCVs have been associated with an increased proportion of
disease associated with NTHi strains.74 An effective NTHi
vaccine candidate will be surface exposed, conserved in het-
erologous strains, immunogenic, and expressed during the
disease state.75 A number of vaccine candidates have been
investigated since 2011 and are summarized in Table 3.
Kodama and colleagues tested the efficacy of nasal vac-
cination with outer membrane protein 6 (P6) in combination
with the chemokine CCL20 in a murine model.76 The addi-
tion of CCL20 resulted in significant increases in IgA and
IgG titers and a subsequent increase in nasopharyngeal
clearance of NTHi. The same group tested the efficacy of
fms-like tyrosine kinase receptor 3 ligand as a mucosal
adjuvant with P6 protein. This pairing also increased dendri-
tic cell recruitment and nasopharyngeal clearance of
NTHi.77,78 Han and colleagues compared the P6 response in
mice when delivered with macrophage-derived chemokine
or with Freund’s adjuvant. Combination of P6 with
macrophage-derived chemokine increased serum IgG titers;
however, there was no statistical difference in survival rate
when the 2 adjuvants were compared.79 Hybridoma cell
lines producing monoclonal antibodies against P6 have been
developed, although efficacy has not been tested to date.80
The outer membrane protein P5 is highly conserved in
all NTHi strains sequenced81-83 and has been shown to be
an effective vaccine candidate in experimental models of
OM.84 Host responses to immunization with P5 have been
described in transcutaneous immunization of NTHi-infected
chinchillas with a chimeric immunogen that includes P5 and
the type IV pilus PilA.84 The authors observed a significant
reduction in the signs of OM and resolution of mucosal bio-
films when animals were immunized with the P5 chimeric
immunogen.
Additional work has focused on NTHi protein E and pro-
tein F. Singh and colleagues demonstrated that peptides cor-
responding to surface-exposed regions of protein E were
immunogenic in mice and that antibodies to these peptides
bound protein E on the bacterial cell surface.85 Mice immu-
nized with a truncated form of the highly conserved protein
F adhesin cleared NTHi infections significantly earlier than
mice treated with a control peptide.86
Serum antibody responses were measured to outer mem-
brane proteins D, P6, and 26 of NTHi in otitis-prone and
non-otitis-prone children. Otitis-prone children mount less
IgG serum antibody response toward all 3 protein antigens,
possibly linked to recurrent infections.87 Recent work
defined outer membrane protein 26 T- and B-cell epitopes,
which will improve existing NTHi vaccines.88
Winter and coworkers examined the ability of antisera
raised against purified high molecular weight (HMW) pro-
teins HMW1/HMW2 or recombinant Hia proteins to med-
iate opsonophagocytic killing of a large panel of NTHi
strains.89 The 3 HMW1/HMW2 antisera mediated killing of
48 of 65 HMW1/HMW2-expressing strains, and the 2 Hia
antisera mediated killing of 15 of 24 Hia-expressing strains.
Thus, a vaccine formulated with a limited number of
HMW1/HMW2 and Hia proteins might provide protection
against disease caused by most NTHi strains.
Davis and coworkers reported on the prevalence, distri-
bution, and sequence diversity of hmwA among a large
Table 2. Protein Vaccine Antigens of Streptococcus pneumoniae at Various Stages of Development.
Antigen Molecular Mass, kDa Putative Function and Other Features Referencea
Ply/pneumolysoid 53 Cholesterol-dependent toxin 57, 58
PhtD; PhtE 95; 115 Histidine-triad proteins 70, 71
PcpA 79 Choline binding protein, adhesin 70, 107
NanA 110 Neuraminidase A, sialidase activity No new information
PsaA 35 Manganese ABC transport substrate binding protein 57, 70, 71
CbpA/PspC 79; smaller fragments
for fusion also being used
Choline binding protein, binds complement
factors and polymeric IG receptor
58
SP1298b 35 DHH subfamily 1 protein, cyclic-AMP
phosphodiesterase
59
SP2205b 73 DHH subfamily 1 protein, cyclic-AMP
phosphodiesterase
59
Pilus-1 Adherence 60
Whole-cell vaccine Not applicable No publications,
under development
aReferences from July 2011 to June 2015.
bNewly identified vaccine antigen from previous report.
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collection of commensal and OM derived NTHi.90hmwA
was detected in 61% of NTHi and was significantly more
prevalent among OM isolates than commensal isolates.
Almost all of the hmwA-positive isolates possessed 2 hmw
loci. The authors also determined the DNA sequence of the
hmwA binding region of 33 isolates and found that the
average amino acid identity across all hmwA sequences
was 62%. Phylogenetic analyses of the hmwA binding
revealed 4 distinct sequence clusters, and the majority of
hmwA sequences (83%) belonged to 1 of 2 dominant
sequence clusters. These data would be important to con-
sider in any vaccine development efforts involving the
HMW1/HMW2 proteins.
M catarrhalis
Prevention of bacterial OM will also require vaccines
directed at M catarrhalis. Several surface proteins of M cat-
arrhalis are in various stages of development as vaccine
antigens91 and are summarized in Table 4. Since the previ-
ous report, a promising M catarrhalis antigen, substrate-
binding protein, has been identified.92 Immunization of
mice with substrate-binding protein induces enhanced
clearance in the mouse pulmonary clearance model.92
Smidt et al93 conducted a comprehensive antigen screen to
identify potential M catarrhalis vaccine candidates. Three
antigens induced significantly faster clearance than
OmpCD or adjuvant alone in a mouse pulmonary clearance
model. The most efficacious antigen, Msp22, was deter-
mined to be a heme binding protein.93 Immunization with
a polypeptide shared by filamentous hemagglutinin-like
proteins MhaB1 and MhaB2 induced antibodies that inter-
fered with M catarrhalis colonization of the chinchilla
nasopharynx.94 Advances in characterization of other puta-
tive vaccine antigens include oligopeptide permease A93,95
and detoxified lipooligosaccharide.96,97
As described in the 2011 report, the lack of good animal
models for M catarrhalis remains a challenge to vaccine
development.3 The mouse pulmonary clearance model is the
most widely used model for assessing vaccine antigens of M
catarrhalis. The model yields reproducible results, and immu-
nization with selected antigens induces enhanced clearance,
which has been interpreted as a protective response. However,
the model does not simulate human disease, and induction of
enhanced clearance in the mouse model has not yet been cor-
related with protection in humans. M catarrhalis is cleared
readily from the middle ear of chinchillas after direct instilla-
tion. Since the last report, 3 studies have successfully used the
chinchilla model to study M catarrhalis colonization and/or
infection. As part of a study of global transcriptome expression
by M catarrhalis, Hoopman et al inoculated chinchillas intra-
nasally and demonstrated nasopharyngeal colonization that
persisted for 72 hours.98 Brockson et al demonstrated that
intranasal coinfection with respiratory syncytial virus and
NTHi predisposed to M catarrhalis induced ascending OM in
the chinchilla.99M catarrhalis was cultured from the nasophar-
ynx and middle ear in the majority of animals for up to 17
days. Finally, Shaffer et al demonstrated nasopharyngeal colo-
nization of chinchillas by M catarrhalis for up to 7 days as
part of evaluating MhaB1 and MhaB2 as potential vaccine
antigens.94 These approaches show promise in testing M catar-
rhalis vaccine antigens in the chinchilla, which has been a
valuable model in evaluating vaccine antigens of NTHi and S
pneumoniae.
Vaccine Delivery Methods
Multiple studies utilize a subcutaneous route to explore
novel vaccine candidates for the prevention of OM.58,92,94,97
The ability to deliver bacterial antigens for the prevention
of OM via an intranasal route also continues to garner
momentum.56,61,83,93 As an example, Xu et al investigated
intranasal immunization using PsaA protein of S pneumo-
niae delivered with chitosan in the form of nanoparticles
and demonstrated greater protection against AOM following
middle ear challenge with a serotype 14 pneumococcus
compared with delivery of naked PsaA.56 There has also
been a great deal of recent activity in the assessment of
alternative delivery methods, including transcutaneous and
maternal immunization for OM vaccine candidates.
Transcutaneous
Since 2011, there have been 3 reports of transcutaneous
immunization to prevent OM due to NTHi. Novotny et al
Table 3. Protein Vaccine Antigens of Haemophilus influenzae at Various Stages of Development.
Antigen Molecular Mass, kDa Putative Function and Other Features Referencea
Protein D 42 Adherence to epithelial cells 42-47
Protein E 16 Multifunctional adhesin 72, 108
Protein F 30 Binds vitronectin and laminin 109, 110
OMP P5 27 Binds factor H, adherence to epithelial cells 84
PilA 15 Twitching motility, adherence, competence, biofilm formation 84
OMP P6 16 Structural role 77-80
OMP26 26 Skp family of translocation proteins 88
HMW1; HMW2 125; 120 Adherence 89
Hia 114 Adherence 89
aReferences from July 2011 to June 2015.
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immunized chinchillas by rubbing a chimeric OMP P5 and
type IV pili immunogen onto the inner surface of their outer
ears.84,100 The authors demonstrated protective efficacy
against development of OM and rapid resolution of estab-
lished disease.84,100 Novotny et al combined the chimeric
OMP P5 and type IV pili immunogen and a bacterial DNA-
binding protein, integration host factor, and demonstrated
that this combination of immunogens resulted in signifi-
cantly earlier eradication of NTHi from planktonic and
adherent populations in the middle ear, disruption of muco-
sal biofilms, and rapid resolution of signs of disease as com-
pared with controls.101
Maternal Immunization
Immunization of pregnant women has been proposed as a
potentially effective immunization strategy to protect infants
from OM. van Santen et al reported that maternal influenza
vaccination and infant receipt of PCV confer greater protec-
tion from OM than PCV alone.102 Conversely, Daly and
colleagues reported discouraging results of a randomized
trial of pregnant women given either an investigational 9-
valent PCV vaccine or a placebo in the last trimester of
pregnancy; all infants received Prevnar at 2, 4, 6, and 12
months.103 Immunizing pregnant women with PCV-9
increased infants’ risk of AOM in the first 6 months of life.
The authors attributed this outcome to decreased infant anti-
body responses to the vaccine serotypes delivered in
Prevnar due to dampening by high levels of passively
acquired pneumococcal antibodies and/or altered B lympho-
cyte immune responses when exposed to these polysacchar-
ide antigens in utero.
Implications for Practice
Several studies demonstrate the positive impact of PCV7,
PCV13, and PHiD-CV on pneumococcal OM, recurrent
OM, OM visits, and tympanostomy tube insertions follow-
ing introduction. While effective for pneumococcal OM,
PHiD-CV may be less broadly protective for NTHi than
originally envisioned. Neither PCV7 nor PCV13 appears to
have substantial impact on development of complex OM in
indigenous Australian children. There are limitations to the
overall impact of PCVs because of serotype replacement.55
Emerging S pneumoniae serotypes prevalent as causes of
OM are 35B, 23A, 23B, 15A, 15B/C, 16F, and 21. A 15-
valent PCV is in development, but there are technical lim-
itations to the number of serotypes that can be included in
vaccines, and the complexity of manufacturing has resulted
in relatively high prices for multivalent PCVs that make
them unaffordable for many developing countries. Of con-
cern, there are significant challenges to licensure of new
pneumococcal vaccines; PCV13 and PHiD-CV were
approved on the basis of immunologic noninferiority and
safety as compared with PCV7.55 Licensing criteria and cor-
relates of protection for protein-based and whole-cell vac-
cines have not been defined.
Future efforts are needed to develop more effective influ-
enza vaccines with robust, long-lasting cross-strain protec-
tion. Since the last review in 2011, there are no additional
studies on the use of passive or active immune prophylaxis
against respiratory syncytial virus infection for protection
against AOM. Research is needed to develop vaccines against
other respiratory viruses, including rhinoviruses, respiratory
syncytial virus, parainfluenza viruses, and adenoviruses.
Table 4. Vaccine Antigens of Moraxella catarrhalis at Various Stages of Development.
Antigen Molecular Mass, kDa Putative Function and Other Features Referencea
MID/Hag 200 Adhesin, binds IgD, hemagglutinin 111
MchA1, MchA2; MhaB1, MhaB2 184; 201 Filamentous hemagglutinin-like adhesin 94
McmA 110 Metallopeptidase-like adhesin
OppA ~80 Oligopeptide permease 93, 95
Msp 75 ~75 Homology to succinic dehydrogenase
McaP 66 Adhesin and phospholipase B
UspA2 62 (oligomer) Binds complement, vitronectin, and laminin 112, 113
OMP E 50 Putative fatty acid transport
OMP CD 45 OMP A–like protein, binds mucin, adhesin 93
M35 ~35 Porin, conserved with one variable loop 114
SBP2b ~30 Substrate binding protein of an ABC transporter 92
OMP G1a ~29 Lipoprotein, putative copper transport protein
OMP G1b ~29 Surface molecule
OlpA 24 Homologous with Neisseria Opa adhesins 115
Msp 22 ~22 Surface lipoprotein 93
Type IV pili 16 Adhesin, transformation, biofilm formation 116
Lipooligosaccharide 2.5-4 Detoxified form is potential vaccine antigen 96, 97, 117, 118
aReferences from July 2011 to June 2015.
bNewly identified vaccine antigen from previous report.
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There are ongoing needs for vaccines that specifically
target NTHi and M catarrhalis–induced OM due to the
shifting microbiology of OM after broad use of PCVs.
Additional important research goals include better integra-
tion of our understanding of those aspects of the microbiol-
ogy of the nasopharynx and OM that could confound
clinical trial outcomes, such as the culture-negative status of
middle ear fluids despite robust biofilms and the potential
presence of H haemolyticus in the nasopharynx; and the
need for more sophisticated testing after delivery of an
NTHi vaccine antigen to detect loss of cells that express
that antigen (instead of just 1/2 scoring) to better gauge
the effectiveness of the immunization on nasopharyngeal
colonization (and more akin to current methods to demon-
strate the loss of vaccine serotypes of the pneumococcus
after delivery of whatever valent PCV is being used).
Critical Future Research Objectives
1. Identification of correlates of protection for AOM.
2. Urgent need to move several already well-
characterized candidate vaccine antigens from animal
studies to human trials.
3. Further development of alternative vaccination deliv-
ery methods, including maternal immunization.
4. Testing of M catarrhalis vaccine candidates in
novel animal models.
5. Continued development of noncapsular vaccine
antigens for pneumococcal OM.
6. Identification and characterization of additional
candidate vaccine antigens of bacterial and viral
OM pathogens.
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